Meeting Banner
Abstract #2728

Association between cardiac iron clereance and hepatic siderosis by T2* MRI in thalassemia major patients

Antonella Meloni1, Laura Pistoia1, Nicolò Schicchi2, Gennaro Restaino3, Paolo Preziosi4, Vincenzo Positano1, Monica Benni5, Maria Paola Smacchia6, Daniele De Marchi1, and Alessia Pepe1

1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, 2Azienda Ospedaliero-Universitaria Ospedali Riuniti "Umberto I-Lancisi-Salesi", Ancona, Italy, 3Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy, 4Ospedale Sandro Pertini, Roma, Italy, 5Policlinico S. Orsola "L. e A. Seragnoli", Bologna, Italy, 6Policlinico Umberto 1, Roma, Italy

We evaluated in thalassemia major (TM) if the cardiac efficacy of the three iron chelators (Desferrioxamine, Deferiprone, and Deferasirox) was influenced by hepatic iron levels over a follow up of 18 months. In patients treated with Deferasirox and Deferiprone percentage changes in cardiac R2* over 18 months were associated with final liver iron concentration (LIC) and percentage LIC changes. In no chelation group percentage changes in cardiac R2* were influenced by initial LIC or initial cardiac R2*.

This abstract and the presentation materials are available to members only; a login is required.

Join Here